Biocon Secures Approval for Generic Liraglutide in India, Expanding Diabetes Treatment Options Jun 03, 2025
Biocon has obtained regulatory approval for its generic version of Victoza (Liraglutide) to treat Type 2 diabetes in India. This approval expands Biocon's diabetes care portfolio and could potentially increase access to affordable diabetes treatment for millions of Indians. The introduction of generic Liraglutide is expected to increase competition in the diabetes care market, potentially leading to lower treatment costs and more options for patients. Launch date and pricing details are yet to be announced.